Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

Background: Most patients with non-small cell lung cancer (NSCLC) experience disease progression after first-line treatment. The efficacy and safety of the nab-paclitaxel (nab-PTX) and bevacizumab combination as the second or further line of treatment in patients with advanced NSCLC have not been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Hao, Xuezhi, Zhu, Yixiang, Mu, Yuxin, Wang, Shouzheng, Li, Junling, Xing, Puyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532494/
https://www.ncbi.nlm.nih.gov/pubmed/33033525
http://dx.doi.org/10.7150/jca.47072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532494/
https://www.ncbi.nlm.nih.gov/pubmed/33033525
http://dx.doi.org/10.7150/jca.47072

Ejemplares similares